{"version":"1.0","type":"rich","provider_name":"techandbusiness.org","provider_url":"https://techandbusiness.org","title":"Ocugen plans FDA filings for three eye-disease gene therapies in 2027 and 2028","author_name":"techandbusiness.org · Policy","thumbnail_url":"https://mdb.ad-hoc-news.de/bild/bild-2797098_1920_1080.webp","width":600,"height":400,"html":"<blockquote class=\"tb-newswire-embed\" style=\"max-width:600px;border-left:3px solid #22d3ee;padding:12px 16px;margin:0;font-family:-apple-system,system-ui,sans-serif;background:#09090b;border-radius:0 8px 8px 0;\">\n      <p style=\"margin:0 0 8px;font-size:10px;font-weight:600;letter-spacing:0.1em;color:#71717a;\">techandbusiness.org · Policy</p>\n      <p style=\"margin:0 0 8px;font-size:18px;font-weight:700;line-height:1.3;color:#fff;\"><a href=\"https://techandbusiness.org/newswire/MJl9dK3WJdOQN3RO95Pfhc\" style=\"color:#fff;text-decoration:none;\">Ocugen plans FDA filings for three eye-disease gene therapies in 2027 and 2028</a></p>\n      <p style=\"margin:0;font-size:14px;color:#a1a1aa;line-height:1.5;\">Ocugen outlined plans to seek U.S. approval for three experimental gene therapies for serious eye diseases. It expects trial results for OCU400, which targets retinitis pigmentosa, in the first quarte...</p>\n    </blockquote>"}